Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_2
5
100%

Phase Distribution

0

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
5(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 25 (100.0%)

Trials by Status

completed360%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05216224
completedphase_2

A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)

NCT04481685
terminatedphase_2

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

NCT05511519
terminatedphase_2

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

NCT04524858
completedphase_2

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

NCT04247815

Clinical Trials (5)

Showing 5 of 5 trials
NCT05216224Phase 2

ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed
NCT04481685Phase 2

A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)

Completed
NCT05511519Phase 2

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Terminated
NCT04524858Phase 2

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

Terminated
NCT04247815Phase 2

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5